COVRE ALESSIA | Elenco docenti

Di Giacomo, A.M., Chiarion-Sileni, V., Del Vecchio, M., Ferrucci, P.F., Guida, M., Quaglino, P., et al. (2024). Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. EUROPEAN JOURNAL OF CANCER, 199 [10.1016/j.ejca.2024.113531]. - dettaglio
Lofiego, M.F., Piazzini, F., Caruso, F.P., Marzani, F., Solmonese, L., Bello, E., et al. (2024). Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches. JOURNAL OF TRANSLATIONAL MEDICINE, 22(1) [10.1186/s12967-024-05040-x]. - dettaglio
Splendiani, E., Besharat, Z.M., Covre, A., Maio, M., Di Giacomo, A.M., Ferretti, E. (2024). Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?. PHARMACOLOGY & THERAPEUTICS, 256 [10.1016/j.pharmthera.2024.108613]. - dettaglio
Calabrò, L., Bronte, G., Grosso, F., Cerbone, L., Delmonte, A., Nicolini, F., et al. (2024). Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream. FRONTIERS IN IMMUNOLOGY, 14 [10.3389/fimmu.2023.1333661]. - dettaglio
Noviello, T.M.R., Di Giacomo, A.M., Caruso, F.P., Covre, A., Mortarini, R., Scala, G., et al. (2023). Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. NATURE COMMUNICATIONS, 14(1) [10.1038/s41467-023-40994-4]. - dettaglio

Tutte le pubblicazioni